Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-02-12 Sale | 2024-02-12 8:22 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 2,573 | $11.44 | $29,435 | 451,449 (Direct) | View |
| 2024-02-02 Sale | 2024-02-05 7:12 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 8,669 | $11.54 | $100,040 | 529,022 (Direct) | View |
| 2023-10-04 Sale | 2023-10-06 7:18 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 5,482 | $19.5 | $106,926 | 387,691 (Direct) | View |
| 2023-02-13 Sale | 2023-02-14 7:10 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 7,851 | $20.13 | $158,005 | 392,048 (Direct) | View |
| 2022-04-04 Sale | 2022-04-05 6:53 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 17,080 | $50.09 | $855,522 | 247,414 (Direct) | View |
| 2022-02-23 Sale | 2022-02-23 8:12 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 1,913 | $49.1 | $93,921 | 264,494 (Direct) | View |
| 2021-08-18 Purchase | 2021-08-20 12:59 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 9,611 | $52 | $499,748 | 266,685 (Direct) | View |
| 2021-07-01 Sale | 2021-07-06 8:01 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 3,083 | $51.27 | $158,054 | 257,074 (Direct) | View |
| 2021-06-01 Sale | 2021-06-02 8:26 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 3,083 | $54.05 | $166,641 | 260,157 (Direct) | View |
| 2021-05-03 Sale | 2021-05-05 4:27 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 3,083 | $59.24 | $182,635 | 263,240 (Direct) | View |
| 2021-04-05 Sale | 2021-04-06 5:46 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 17,107 | $43.39 | $742,323 | 266,323 (Direct) | View |
| 2021-03-01 Sale | 2021-03-03 4:35 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 3,083 | $41.67 | $128,482 | 283,430 (Direct) | View |
| 2021-02-01 Sale | 2021-02-03 5:56 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 3,083 | $37.56 | $115,805 | 271,513 (Direct) | View |
| 2021-01-04 Sale | 2021-01-06 8:24 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 3,083 | $51.91 | $160,034 | 274,596 (Direct) | View |
| 2020-12-04 Sale | 2020-12-08 8:38 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 13,684 | $52.18 | $714,060 | 277,679 (Direct) | View |
| 2020-12-02 Sale | 2020-12-03 5:56 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 3,083 | $51.47 | $158,681 | 291,363 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-10-21 Option Award | 2024-10-23 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 1,613 | $0 | 38,037 (Direct) | View |
| 2024-09-12 Other | 2024-09-16 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 4,245 | $12.12 | 40,669 (Direct) | View |
| 2024-09-10 Option Award | 2024-09-12 9:00 pm | N/A 2034-09-09 | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 44,300 | $0 | 68,563 (Direct) | View |
| 2024-07-23 Option Award | 2024-07-25 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 1,702 | $0 | 24,263 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-17 5:37 pm | N/A 2034-06-14 | Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director | 45,000 | $0 | 45,000 (Direct) | View |
| 2024-04-24 Option Award | 2024-04-26 9:01 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 1,146 | $0 | 22,561 (Direct) | View |
| 2024-04-24 Tax Withholding | 2024-04-26 9:01 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 123 | $10.9 | 22,561 (Direct) | View |
| 2024-04-03 Disposition | 2024-04-05 4:55 pm | N/A 2030-10-23 | Kinnate Biopharma Inc. | KNTE | Epperly Melissa B Director | 126,251 | $0 | 0 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-05 7:12 pm | N/A 2034-01-31 | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 75,000 | $0 | 529,022 (Direct) | View |
| 2024-01-19 Option Award | 2024-01-23 9:00 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 1,207 | $0 | 21,538 (Direct) | View |
| 2023-10-16 Option Award | 2023-10-18 9:30 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 1,226 | $0 | 20,331 (Direct) | View |
| 2023-09-12 Option Award | 2023-09-14 9:31 pm | N/A 2033-09-11 | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 44,420 | $0 | 45,700 (Direct) | View |
| 2023-07-03 Option Award | 2023-07-06 9:30 pm | N/A N/A | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 1,280 | $0 | 1,280 (Direct) | View |
| 2023-06-15 Option Award | 2023-06-16 7:52 pm | N/A 2033-06-15 | Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director | 45,000 | $0 | 45,000 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-13 6:26 pm | N/A 2033-06-12 | Kinnate Biopharma Inc. | KNTE | Epperly Melissa B Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2023-02-01 Option Award | 2023-02-01 7:07 pm | N/A 2033-01-31 | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 250,000 | $0 | 547,942 (Direct) | View |
| 2022-10-03 Option Award | 2022-10-03 6:42 pm | N/A N/A | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 50,000 | $0 | 297,543 (Direct) | View |
| 2022-07-20 Option Award | 2022-07-25 06:06 am | N/A 2032-07-19 | Roivant Sciences Ltd. | ROIV | Epperly Melissa B Director | 186,916 | $0 | 186,916 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-16 8:03 pm | N/A 2032-06-15 | Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director | 86,467 | $0 | 86,467 (Direct) | View |
| 2022-06-13 Option Award | 2022-06-15 5:00 pm | N/A 2032-06-13 | Kinnate Biopharma Inc. | KNTE | Epperly Melissa B Director | 20,250 | $0 | 20,250 (Direct) | View |
| 2022-02-10 Option Award | 2022-02-14 9:09 pm | N/A 2032-02-09 | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 54,894 | $0 | 304,896 (Direct) | View |
| 2021-10-02 Tax Withholding | 2021-10-04 9:16 pm | N/A N/A | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 17,080 | $67.13 | 250,002 (Direct) | View |
| 2021-06-11 Option Award | 2021-06-14 7:13 pm | N/A 2031-06-11 | Kinnate Biopharma Inc. | KNTE | Epperly Melissa B Director | 20,250 | $0 | 20,250 (Direct) | View |
Ownership | 2021-06-09 9:41 pm | N/A 2031-01-31 | Nautilus Biotechnology Inc. | NAUT | Epperly Melissa B Director | 0 | $0 | 72,561 (Direct) | View |
| 2021-02-11 Option Award | 2021-02-16 7:05 pm | N/A 2031-02-10 | Zentalis Pharmaceuticals Inc. | ZNTL | Epperly Melissa B Chief Financial Officer | 60,000 | $0 | 331,513 (Direct) | View |